WO2021153773A1 - 光老化抑制剤 - Google Patents

光老化抑制剤 Download PDF

Info

Publication number
WO2021153773A1
WO2021153773A1 PCT/JP2021/003369 JP2021003369W WO2021153773A1 WO 2021153773 A1 WO2021153773 A1 WO 2021153773A1 JP 2021003369 W JP2021003369 W JP 2021003369W WO 2021153773 A1 WO2021153773 A1 WO 2021153773A1
Authority
WO
WIPO (PCT)
Prior art keywords
photoaging
vitamin
ultraviolet rays
skin
wavelength
Prior art date
Application number
PCT/JP2021/003369
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
宮沢　和之
レノ ジレ
ビアンカ マッカーシー
哲也 金丸
Original Assignee
株式会社 資生堂
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社 資生堂 filed Critical 株式会社 資生堂
Priority to JP2021574717A priority Critical patent/JPWO2021153773A1/ja
Priority to CN202180011843.XA priority patent/CN115038424A/zh
Publication of WO2021153773A1 publication Critical patent/WO2021153773A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/29—Titanium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations

Definitions

  • the present invention relates to a photoaging inhibitor containing a wavelength converting substance, compositions and products containing such a photoaging inhibitor, and a method for activating the skin using them.
  • the harmful effects of ultraviolet rays on the skin include, for example, skin cancer, photoaging, age spots, wrinkles, and inflammation, which are not preferable from the viewpoint of health and beauty.
  • ultraviolet rays for the purpose of bactericidal effect, considering the balance with the harmful effects of ultraviolet rays, the focus is on protecting them rather than actively using them. The current situation.
  • UV-cut film Therefore, many measures have been taken to protect the skin from UV rays. For example, the use of sunscreen, indoor activities that are not exposed to sunlight, UV-cut hats and clothing, and the use of UV-cut film.
  • An object of the present invention is to provide a novel photoaging inhibitor using ultraviolet rays.
  • a photoaging inhibitor that contains a wavelength converting substance as an active ingredient and suppresses photoaging caused by exposure of the skin to light containing ultraviolet rays.
  • the wavelength conversion substance is a photoaging inhibitor that converts the wavelength of ultraviolet rays contained in incident light and emits emitted light having a wavelength longer than the wavelength of the ultraviolet rays.
  • the photoaging inhibitor according to (1) wherein the ultraviolet rays have a peak wavelength in the range of 200 nm to 400 nm.
  • the photoaging inhibitor according to (1) or (2), wherein the emitted light has a peak wavelength in the range of 450 nm to 700 nm.
  • the wavelength converting substance is selected from allophycocyanin, C-phycocyanin, R-phycocyanin, phycoerythrinin, B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, and R-phycoerythrin.
  • One or more phycocyanin proteins selected from zinc oxide phosphors, magnesium titanate phosphors, and calcium phosphate phosphors; vitamin A, ⁇ -carotenoids, vitamin K, vitamins Selected from B1, Vitamin B2, Vitamin B6, Vitamin B12, Folic Acid, Niacin, Lycopine, Cutinashi, Benibana, Ukon, Cochinil, Perilla, Red Cabbage, Flavonoids, Carotenoids, Kinoids, Porphyrins, Anthocyanins, and Polyphenols 1 Species or multiple components; and / or Red 401, Red 227, Red 504, Red 218, Orange 205 P, Yellow 4, Yellow 5, Green 201, Phycocyanin Conch, Blue 1, Selected from 2,4-diaminophenoxyethanol hydrochloride, Arizulin purple SS, purple 401, black 401, herringdon pink, yellow 401, phycocyanin yellow G, blue 404, red 104, and metaamin
  • the photoaging inhibitor according to any one of (1) to (3), which contains one or more dyes.
  • the wavelength converting substance is selected from allophycocyanin, C-phycocyanin, R-phycocyanin, phycoerythrinin, B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, and R-phycoerythrin.
  • the photoaging inhibitor according to (4) which comprises one or more kinds of vitamin B selected from vitamin B6 and vitamin B12.
  • a beauty method for suppressing photoaging caused by exposure of the subject's skin to light containing ultraviolet rays. (9) A product containing the photoaging inhibitor according to any one of (1) to (5). (10) The product according to (9), wherein the product is for suppressing photoaging caused by exposure of the skin to light containing ultraviolet rays. (11) Passing light, including ultraviolet light, through the product according to (9) or (10); A beauty method for suppressing photoaging caused by exposure of the subject's skin to light containing ultraviolet rays.
  • the present invention can exert a favorable effect on the skin by suppressing photoaging while being exposed to ultraviolet rays.
  • ultraviolet rays are not preferable to the skin, so it is common general technical knowledge in this field to take measures to prevent the skin from being exposed to ultraviolet rays as much as possible.
  • the present invention is very surprising because it is based on the finding that photoaging is suppressed even when exposed to ultraviolet rays and has a favorable effect on the skin.
  • the present invention also provides new uses for the above-mentioned compounds that have been conventionally mainly used as pigments, pigments, ultraviolet scattering agents, ultraviolet absorbers, nutritional components, antioxidants, and the like. Further, the present invention may lead to improvement of quality of life such that even a person who has avoided ultraviolet rays as much as possible for beauty and health reasons can feel like going out positively.
  • FIG. 1 shows the measurement of photoaging by the dermis model.
  • FIG. 2 shows the photoaging inhibitory effect of the zinc oxide phosphor film.
  • FIG. 3 shows the photoaging inhibitory effect of the magnesium titanate phosphor film.
  • FIG. 4 shows the photoaging inhibitory effect of the C-phycocyanin film.
  • the photoaging inhibitor of the present invention contains a wavelength converting substance as an active ingredient.
  • the wavelength conversion substance refers to a substance that converts the wavelength of ultraviolet rays contained in incident light and emits emitted light having a wavelength longer than the wavelength of the ultraviolet rays.
  • Ultraviolet rays may include UVA, UVB, UVC and the like.
  • ultraviolet light is light having a peak wavelength between 200 nm and 400 nm.
  • the incident light such as sunlight may contain ultraviolet rays.
  • the incident light may be ultraviolet rays, or artificially generated ultraviolet rays may be used.
  • the emitted light emitted by the wavelength converting substance has a longer wavelength than ultraviolet rays, and has a peak wavelength of preferably 450 nm to 700 nm, more preferably 500 nm to 700 nm.
  • the emitted light is, for example, but not limited to, 450 nm, 460 nm, 470 nm, 480 nm, 490 nm, 500 nm, 510 nm, 520 nm, 530 nm, 540 nm, 550 nm, 560 nm, 570 nm, 580 nm, 590 nm, 600 nm, 610 nm, 620 nm, 630 nm, 640 nm, It may have one or more peaks in 650nm, 660nm, 670nm, 680nm, 690nm, 700nm, or any range of these values, or in red light, orange light, green light, blue light, etc.
  • the wavelength-converting material exhibits a main wavelength of 450 nm to 700 nm, more preferably 500 nm to 700 nm, of light emitted when excited by excitation light of 200 nm to 400 nm.
  • wavelength converters include: allophicocyanin, C-phycocyanin, R-phycocyanin, phycoerythrinin, B-phycoerythrin, b-phycoerythrin, C-phycoerythrin, R-phy Phycoerythrin and other phycocyanins; vitamin A, ⁇ -carotene, vitamin K, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, niacin, lycopene, cutinashi, benibana, turmeric, cochineal, perilla, red cabbage, flavonoids, carotenoids , Kinoids, porphyrins, anthocyanins, polyphenols, etc.
  • Red 401, Red 227, Red 504, Red 218, Orange 205 P Yellow 4, Yellow 5, Green 201 No., Pyranin Conc, Blue No. 1, Hydrochloride 2,4-diaminophenoxyethanol, Arizulin Purple SS, Purple No. 401, Black No. 401, Herringdon Pink, Yellow No. 401, Benchin Yellow G, Blue No. 404, Red No. 104, Dyes such as metaaminophenol; phosphors doped with inorganic compounds to have fluorescence, for example, blue phosphors containing the amorphous silica particles described in Patent No. 6424656, cerium, phosphorus and / or magnesium.
  • a red phosphor containing a compound in which europium is activated in a mixed crystal of alkaline earth metal sulfide and gallium compound described in Patent No. 6361416 zinc oxide phosphor described in International Publication No. 2018/004006, special feature.
  • Examples thereof include the zinc oxide phosphor described in Kai 2018-131422; the inorganic phosphor described in JP-A-5-117127; and the like.
  • the inorganic phosphor can represent zinc oxide as ZnO: Zn, Zn 1 + z , ZnO 1-x , as described in WO 2018/004006, eg, zinc sulfide, zinc sulfate.
  • the wavelength conversion substance may be obtained from natural products such as animals, plants, and algae by a method such as extraction, or may be obtained by an artificial method such as chemical synthesis.
  • the phycobiliprotein is algae such as blue-green algae such as Spirulina platensis and red algae such as Porphyridium purpureum. It may be prepared by extraction.
  • the zinc oxide phosphor may be produced, for example, by the methods described in International Publication No. 2018/004006, JP-A-2018-131422, and JP-A-5-117127.
  • the magnesium titanate phosphor may be produced by the method described in JP-A-2017-88719.
  • the calcium phosphate phosphor may be produced by the method described in WO 2018/117117.
  • wavelength conversion substances may be composed of the components exemplified above, may be contained, or may be used alone or in combination of a plurality of types, as long as the wavelength conversion effect of the present invention is not impaired. good.
  • other wavelength converting substances such as vitamin B (vitamin B1, vitamin B2, vitamin B6, vitamin B12, etc.) may be mixed with the phycobiliprotein or the inorganic phosphor to aim for a synergistic effect.
  • these components are examples, and any substance exhibiting the wavelength conversion effect of the present invention can be used.
  • the content of the wavelength converting substance in the photoaging inhibitor, composition or product of the present invention is not particularly limited as long as the wavelength conversion effect of the present invention is not impaired, and the type of wavelength converting substance and the photoaging inhibitor or composition are not particularly limited. It can be appropriately determined depending on the intended use. For example, it is arbitrary within the range of 0.01 to 99.99% by weight, 0.1% to 999% by weight, and the like.
  • Photoaging as used in the present invention refers to wrinkles and sagging of the skin formed when the skin is exposed to light containing ultraviolet rays, for example, sunlight or artificial ultraviolet rays.
  • the dermis which is deep in the skin, is mainly composed of collagen, which is produced by fibroblasts, which are strongly bound to each other in the dermis.
  • the binding force between fibroblasts and collagen is weakened, causing damage, resulting in the formation of wrinkles and sagging.
  • the effect of suppressing skin wrinkles and sagging due to photoaging can be determined by, for example, Toshi Taira et al., Cytoprotection and Cytobiology, Vol.4 (January 1986), pp. Can be measured.
  • Recovery from damage caused by UV irradiation of a dermis model made from collagen and fibroblasts can be measured by measuring the contractility of the gel.
  • the administration form of the photoaging inhibitor and the composition of the present invention is arbitrary, but external preparations for the skin such as pharmaceuticals, quasi-drugs, and cosmetics are preferable in order to activate the skin by exposing the skin to light containing ultraviolet rays. In some cases.
  • the photoaging inhibitor or composition of the present invention is used as an external preparation for skin, the dosage form, application method, number of administrations and the like can be arbitrarily determined.
  • the dosage form, application method, number of administrations and the like can be arbitrarily determined.
  • the form of lotion, spray, oil, cream, milky lotion, gel, sunscreen, suntan, etc. regularly or irregularly, for example, once to several times a day, such as in the morning, noon, and evening. It may be applied to the skin each time before going out, outdoor activities, marine sports, skiing, etc. before being expected to be exposed to the sun.
  • the photoaging inhibitor and composition of the present invention may be used, for example, as an excipient, a preservative, a thickener, a binder, a disintegrant, a dispersant, a stabilizer, a gelling agent, and an oxidation agent, if necessary.
  • Additives such as Japanese agents can be arbitrarily selected and used in combination. Further, in order to enhance the effect of the present invention, other photoaging inhibitors and the like may be used in combination.
  • the present invention contains the photoaging inhibitor of the present invention, and for activating the skin by exposing the skin to light containing ultraviolet rays, for example, a sun visor, a hat, clothing, gloves, a screen film, a window spray.
  • ultraviolet rays for example, a sun visor, a hat, clothing, gloves, a screen film, a window spray.
  • products such as creams, window materials, and wall materials. Similar to the above, the use of additives and the like in the product of the present invention and the form of the product are also arbitrary.
  • the present invention also provides a method for producing the photoaging inhibitor, composition or product of the present invention. It also provides a method for activating the subject's skin, where the method is to apply the photoaging inhibitor or composition of the invention to the subject's skin; or to expose the product of the invention to UV light.
  • the photoaging inhibitor, composition and product including passing light containing, converts the wavelength of the ultraviolet light contained in the incident light to emit emitted light having a wavelength longer than the wavelength of the ultraviolet light, which is preferable. Allows ultraviolet light having a peak wavelength of 200 nm to 400 nm to pass as light having a peak wavelength of preferably 450 nm to 700 nm, more preferably 500 nm to 700 nm.
  • the method for activating the subject's skin is for the purpose of beauty and may not be the treatment method used by doctors and healthcare professionals.
  • the present invention also provides a cosmetological counseling method that supports a cosmetological act of the subject, including presenting the cosmetological method, photoaging inhibitor, composition or product of the present invention to the subject.
  • the wavelength conversion material was prepared as follows.
  • Lumate G is a zinc oxide phosphor obtained by doping ZnO with a sulfur-containing compound and then firing it as described in International Publication No. 2018/004006.
  • the absorption spectrum has a peak wavelength at 365 nm, and the emission spectrum peaks at 510 nm. Had a wavelength.
  • Magnesium titanate phosphor Lumate R manufactured by Sakai Chemical Industry Co., Ltd. was used.
  • Lumate R is a magnesium titanate phosphor doped with MgTiO3 with manganese.
  • the absorption spectrum has a peak wavelength at 365 nm, and the emission spectrum has a peak wavelength in the band of 660 to 680 nm.
  • (3) C-Phycocyanin C-phycocyanin is obtained from Spirulina platensis extract, the absorption spectrum has a peak wavelength at 350 nm, and the emission spectrum has a peak wavelength at 640 nm and 700 nm. Was there.
  • Experiment 2 As in Experiment 1, a dermis model was prepared, and a zinc oxide phosphor film (Film G), a magnesium titanate phosphor film (Film R), or a film (blue dye) containing an aqueous solution of C-phycocyanin was placed on it. rice field. Then, artificial sunlight irradiation (40 min or 80 min at a distance of 70 cm) was performed. The control was the one irradiated with artificial sunlight without the above-mentioned wavelength conversion substance film. The results are shown in FIGS. 2 to 4. Collagen gel contraction was observed in all the samples irradiated with artificial sunlight through zinc oxide phosphor, magnesium titanate phosphor, and C-phycocyanin, and it was confirmed that the fibroblasts were not damaged.
  • FIGS. 2 to 4 Collagen gel contraction was observed in all the samples irradiated with artificial sunlight through zinc oxide phosphor, magnesium titanate phosphor, and C-phycocyanin, and it was confirmed that the

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
PCT/JP2021/003369 2020-01-31 2021-01-29 光老化抑制剤 WO2021153773A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021574717A JPWO2021153773A1 (zh) 2020-01-31 2021-01-29
CN202180011843.XA CN115038424A (zh) 2020-01-31 2021-01-29 光老化抑制剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-015614 2020-01-31
JP2020015614 2020-01-31

Publications (1)

Publication Number Publication Date
WO2021153773A1 true WO2021153773A1 (ja) 2021-08-05

Family

ID=77078135

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/003369 WO2021153773A1 (ja) 2020-01-31 2021-01-29 光老化抑制剤

Country Status (3)

Country Link
JP (1) JPWO2021153773A1 (zh)
CN (1) CN115038424A (zh)
WO (1) WO2021153773A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117919109A (zh) * 2024-03-22 2024-04-26 广州中医药大学(广州中医药研究院) 一种紫苏宁类化合物在制备皮肤抗衰老产品中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006316065A (ja) * 2005-05-10 2006-11-24 L'oreal Sa 化粧料組成物
CN105055251A (zh) * 2015-08-29 2015-11-18 云南蓝钻生物科技股份有限公司 一种抗衰老化妆品及其制备方法
JP2017122075A (ja) * 2016-01-08 2017-07-13 花王株式会社 水中油型皮膚化粧料
KR20190005369A (ko) * 2017-07-06 2019-01-16 한국 한의학 연구원 씨-피코시아닌을 유효성분으로 함유하는 피부 주름의 예방 또는 개선용 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117127A (ja) * 1991-10-02 1993-05-14 Shiseido Co Ltd 蛍光化粧料

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006316065A (ja) * 2005-05-10 2006-11-24 L'oreal Sa 化粧料組成物
CN105055251A (zh) * 2015-08-29 2015-11-18 云南蓝钻生物科技股份有限公司 一种抗衰老化妆品及其制备方法
JP2017122075A (ja) * 2016-01-08 2017-07-13 花王株式会社 水中油型皮膚化粧料
KR20190005369A (ko) * 2017-07-06 2019-01-16 한국 한의학 연구원 씨-피코시아닌을 유효성분으로 함유하는 피부 주름의 예방 또는 개선용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Shining new cosmetic raw material, Inorganic fluorescent powder Lumate series", FRAGRANCE JOURNAL, vol. 43, no. 7, 15 July 2015 (2015-07-15), pages 62 - 63 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117919109A (zh) * 2024-03-22 2024-04-26 广州中医药大学(广州中医药研究院) 一种紫苏宁类化合物在制备皮肤抗衰老产品中的应用

Also Published As

Publication number Publication date
JPWO2021153773A1 (zh) 2021-08-05
CN115038424A (zh) 2022-09-09

Similar Documents

Publication Publication Date Title
WO2020202764A1 (ja) 細胞賦活剤
WO2021153773A1 (ja) 光老化抑制剤
KR102534801B1 (ko) 자외선 및 블루라이트 차단용 화장료 조성물
WO2021153785A1 (ja) コラーゲン産生能の維持または促進剤
WO2021153781A1 (ja) コラーゲン糖化抑制剤
WO2021153771A1 (ja) ヒアルロン酸産生促進剤
WO2020204193A9 (ja) 紫外線波長変換物質を含有する組成物
WO2021153776A1 (ja) 血管新生抑制剤
WO2021153780A1 (ja) 抗酸化剤又は皮膚ストレス抑制剤
WO2021153788A1 (ja) 皮膚バリア機能亢進剤
WO2021153783A1 (ja) 炎症抑制剤
JP7509541B2 (ja) 紫外線波長変換物質及び有機系油相増粘剤を含有する乳化組成物
JP2024031642A (ja) 可視光によりリボフラビンの生理作用を増強するための美容方法
JP7509542B2 (ja) 紫外線波長変換物質を含有する組成物
US20220160604A1 (en) Emulsion composition comprising ultraviolet wavelength conversion substance and organic oily phase thickener
JP2024031635A (ja) 可視光によりフラボノイドの生理作用を増強するための美容方法
JP7509540B2 (ja) 紫外線波長変換物質を含有する水中油型乳化組成物
JP2024096356A (ja) 紫外線波長変換物質を含有する組成物
CN116999342A (zh) 一种化妆品组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21747943

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021574717

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21747943

Country of ref document: EP

Kind code of ref document: A1